Biomarker: 1-methyladenosine

Histology type: endometrioid endometrial carcinoma

Country: Slovenia

Region: Maribor

Study type: prospective study

Followed up time :

Subgroup 1 number: endometrial cancer

Subgroup 2 name : no malignancie

Subgroup 1 number: 15

Subgroup 2 number: 21

Cohort statistics: Mean (SD)

Description: 1-methyladenosine identified as potential diagnostic biomarkers for EC. Additionally, these identified metabolites may provide additional insight into cancer cell metabolism.

Sample type : serum

Sample method: HPLC-TQ/MS

Subgroup 1 age: 64±14

Subgroup 2 age: 54±19

Expression figure legend: ROC curves and boxplot representations for 4 top performing biomarkers as analyzed by univariate analysis.

Expression figure link: https://ars.els-cdn.com/content/image/1-s2.0-S1896112620300456-gr4_lrg.jpg

Status: Detected and Quantified

HMDB ID: HMDB0003331

Secondary accession numbers: HMDB03331

Common name: 1-Methyladenosine

Description: 1-Methyladenosine, also known as M1A, belongs to the class of organic compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Precise m6A mapping by m6A-CLIP/IP (briefly m6A-CLIP) revealed that a majority of m6A locates in the last exon of mRNAs in multiple tissues/cultured cells of mouse and human, and the m6A enrichment around stop codons is a coincidence that many stop codons locate round the start of last exons where m6A is truly enriched. The methylation of adenosine is directed by a large m6A methyltransferase complex containing METTL3 as the SAM-binding sub-unit. Insulin-like growth factor-2 mRNA-binding proteins 1, 2, and 3 (IGF2BP1-3) are reported as a novel class of m6A readers.

Chemical formula: C11H15N5O4

Chemical taxonomy description: Belongs to the class of organic compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.

Chemical taxonomy kingdom: Organic compounds

Chemical taxonomy super class: Nucleosides, nucleotides, and analogues

Chemical taxonomy class: Purine nucleosides 

Chemical taxonomy sub class: Not Available

Direct parent: Purine nucleosides

Alternative parents: Glycosylamines Pentoses Purines and purine derivatives Pyrimidines and pyrimidine derivatives N-substituted imidazoles Imidolactams Tetrahydrofurans Heteroaromatic compounds Secondary alcohols Oxacyclic compounds Azacyclic compounds Primary alcohols Organopnictogen compounds Organonitrogen compounds Hydrocarbon derivatives

Substituents: Purine nucleoside Glycosyl compound N-glycosyl compound Pentose monosaccharide Imidazopyrimidine Purine Monosaccharide N-substituted imidazole Imidolactam Pyrimidine Heteroaromatic compound Azole Imidazole Tetrahydrofuran Secondary alcohol Organoheterocyclic compound Azacycle Oxacycle Primary alcohol Organopnictogen compound Organooxygen compound Organonitrogen compound Alcohol Organic oxygen compound Hydrocarbon derivative Organic nitrogen compound Aromatic heteropolycyclic compound

Molecular framework: Aromatic heteropolycyclic compounds

Physiological effect: Health effect Renal system and urinary system Renal disorder Kidney disease (HMDB: HMDB0003331) Cancer Leukemia (HMDB: HMDB0003331) Ovarian cancer (HMDB: HMDB0003331) Colorectal cancer (HMDB: HMDB0003331) Cholangiocarcinoma (HMDB: HMDB0003331) Cervical cancer (HMDB: HMDB0003331) Uremia (HMDB: HMDB0003331) Digestive system disorder Gastrointestinal disorder Stomach cancer (HMDB: HMDB0003331) Hepatobiliary disorder Hepatocellular carcinoma (HMDB: HMDB0003331)

Disposition: Biofluid or Excreta Blood (HMDB: HMDB0003331) Urine (HMDB: HMDB0003331) Organ Prostate (HMDB: HMDB0003331) Placenta (HMDB: HMDB0003331) Excreta Biofluid or Excreta Urine (PMID: 15116424) Breast Milk (PMID: 7702711) Feces (PMID: 27543620) Non-excretory biofluid Biofluid or Excreta Blood (PMID: 7482520) Cellular substructure Cytoplasm (HMDB: HMDB0003331)

Source Endogenous Endogenous (HMDB: HMDB0003331) Exogenous Food

Associated disorders diseases: Leukemia Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8. [PubMed:7482520 ] Ovarian cancer Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8. [PubMed:7482520 ] Woo HM, Kim KM, Choi MH, Jung BH, Lee J, Kong G, Nam SJ, Kim S, Bai SW, Chung BC: Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta. 2009 Feb;400(1-2):63-9. doi: 10.1016/j.cca.2008.10.014. Epub 2008 Oct 30. [PubMed:19010317 ] Uremia Niwa T, Takeda N, Yoshizumi H: RNA metabolism in uremic patients: accumulation of modified ribonucleosides in uremic serum. Technical note. Kidney Int. 1998 Jun;53(6):1801-6. [PubMed:9607216 ] Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8. [PubMed:7482520 ] Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934-43. doi: 10.1046/j.1523-1755.2003.00924.x. [PubMed:12675874 ] Kidney disease Niwa T, Takeda N, Yoshizumi H: RNA metabolism in uremic patients: accumulation of modified ribonucleosides in uremic serum. Technical note. Kidney Int. 1998 Jun;53(6):1801-6. [PubMed:9607216 ] Stomach cancer Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8. [PubMed:7482520 ] Hepatocellular carcinoma Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8. [PubMed:7482520 ] Cholangiocarcinoma Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8. [PubMed:7482520 ] Colorectal cancer Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8. [PubMed:7482520 ] Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ] Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ] Cervical cancer Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8. [PubMed:7482520 ]

KEGG compound ID: C02494

CPD link: https://www.genome.jp/dbget-bin/www_bget?cpd:C02494

HMDB link: https://hmdb.ca/metabolites/HMDB0003331

PubChem CID: 129892586

PubChem CID link: https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxyhexadecenoylcarnitine